Literature DB >> 34168430

Synthesis, Radiolabeling, and Preliminary in vivo Evaluation of [68Ga] IPCAT-NOTA as an Imaging Agent for Dopamine Transporter.

Shiou-Shiow Farn1,2, Kang-Wei Chang3, Wan-Chi Lin1, Hung-Man Yu1, Kun-Liang Lin1, Yu-Chin Tseng1, Yu Chang1, Chung-Shan Yu2,4, Wuu-Jyh Lin1.   

Abstract

INTRODUCTION: Novel radiotracer development for imaging dopamine transporters is a subject of interest because although [99mTc]TRODAT-1, [123I]β-CIT, and [123I]FP-CIT are commercially available; 99Mo/99mTc generator is in short supply and 123I production is highly dependent on compact cyclotron. Therefore, we designed a novel positron emission tomography (PET) tracer based on a tropane derivative through C-2 modification to conjugate NOTA for chelating 68Ga, a radioisotope derived from a 68Ge/68Ga generator.
METHODS: IPCAT-NOTA 22 was synthesized and labeled with [68Ga]GaCl4 - at room temperature. Biological studies on serum stability, LogP, and in vitro autoradiography (binding assay and competitive assay) were performed. Furthermore, ex vivo autoradiography, biodistribution, and dynamic PET imaging studies were performed in Sprague Dawley rats.
RESULTS: [68Ga]IPCAT-NOTA 24 obtained had a radiochemical yield of ≥90% and a specific activity of 4.25 MBq/nmol. [68Ga]IPCAT-NOTA 24 of 85% radiochemical purity (RCP%) was stable at 37°C for up to 60 minutes in serum with a lipophilicity of 0.88. The specific binding ratio (SBR%) reached 15.8 ± 6.7 at 60 minutes, and the 85% specific uptake could be blocked through co-injection at 100- and 1000-fold of the cold precursor in in vitro binding studies. Tissue regional distribution studies in rats with [68Ga]IPCAT-NOTA 24 showed striatal uptake (0.02% at 5 minutes and 0.007% at 60 minutes) with SBR% of 6%, 25%, and 62% at 5-15, 30-40, and 60-70 minutes, respectively, in NanoPET studies. The RCP% of [68Ga]IPCAT-NOTA 24 at 30 minutes in vivo remained 67.65%.
CONCLUSION: Data described here provide new information on the design of PET probe of conjugate/pendent approach for DAT imaging. Another chelator or another direct method of intracranial injection must be used to prove the relation between [68Ga]IPCAT-NOTA 24 uptake and transporter localization.
© 2021 Farn et al.

Entities:  

Keywords:  Ga-68; Parkinson disease; dopamine transporter

Mesh:

Substances:

Year:  2021        PMID: 34168430      PMCID: PMC8216701          DOI: 10.2147/DDDT.S288600

Source DB:  PubMed          Journal:  Drug Des Devel Ther        ISSN: 1177-8881            Impact factor:   4.162


  21 in total

1.  Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.

Authors:  Morten Ziebell; Signe Holm-Hansen; Gerda Thomsen; Aase Wagner; Peter Jensen; Lars H Pinborg; Gitte Moos Knudsen
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

Review 2.  Matching chelators to radiometals for radiopharmaceuticals.

Authors:  Eric W Price; Chris Orvig
Journal:  Chem Soc Rev       Date:  2013-10-30       Impact factor: 54.564

3.  Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Vikas Prasad; Harshad Kulkarni; Sven-Petter Haugvik; Merten Hommann; Richard Paul Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-31       Impact factor: 9.236

Review 4.  Continued rapid growth in (68) Ga applications: update 2013 to June 2014.

Authors:  Irina Velikyan
Journal:  J Labelled Comp Radiopharm       Date:  2015-02-17       Impact factor: 1.921

5.  Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals.

Authors:  D D Dishino; M J Welch; M R Kilbourn; M E Raichle
Journal:  J Nucl Med       Date:  1983-11       Impact factor: 10.057

6.  Evaluation of gallium-68 tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake.

Authors:  C S Cutler; M C Giron; D E Reichert; A Z Snyder; P Herrero; C J Anderson; D A Quarless; S A Koch; M J Welch
Journal:  Nucl Med Biol       Date:  1999-04       Impact factor: 2.408

7.  Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.

Authors:  Anissa Abi-Dargham; Lawrence S Kegeles; Yolanda Zea-Ponce; Osama Mawlawi; Diana Martinez; Vivian Mitropoulou; Karen O'Flynn; Harold W Koenigsberg; Ronald Van Heertum; Thomas Cooper; Marc Laruelle; Larry J Siever
Journal:  Biol Psychiatry       Date:  2004-05-15       Impact factor: 13.382

8.  Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys.

Authors:  Kuo-Hsing Ma; Wen-Sheng Huang; Chien-Hsing Chen; Shin-Zong Lin; Shiaw-Pyng Wey; Gann Ting; Shwun-De Wang; Hwan-Wun Liu; Jiang-Chuan Liu
Journal:  Nucl Med Biol       Date:  2002-07       Impact factor: 2.408

9.  Ex vivo evaluation of N-(3-[18F]fluoropropyl)-2 beta-carbomethoxy-3 beta-(4-fluorophenyl)nortropane in rats.

Authors:  Teija Koivula; Päivi Marjamäki; Merja Haaparanta; Veronica Fagerholm; Tove Grönroos; Tiina Lipponen; Outi Perhola; Jouko Vepsäläinen; Olof Solin
Journal:  Nucl Med Biol       Date:  2008-02       Impact factor: 2.408

10.  Detection of Active Caspase-3 in Mouse Models of Stroke and Alzheimer's Disease with a Novel Dual Positron Emission Tomography/Fluorescent Tracer [68Ga]Ga-TC3-OGDOTA.

Authors:  Valeriy G Ostapchenko; Jonatan Snir; Mojmir Suchy; Jue Fan; M Rebecca Cobb; Blaine A Chronik; Michael Kovacs; Vania F Prado; Robert H E Hudson; Stephen H Pasternak; Marco A M Prado; Robert Bartha
Journal:  Contrast Media Mol Imaging       Date:  2019-01-14       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.